Hoiyda A Abdel Rasol1, Hanan Helmy2, Sherine El-Mously3, Margeret A Aziz4, Hossam El Bahaie5. 1. Faculty of Applied Medical Sciences, Taibah University, Al Madinah Al Monawara, Kingdom of Saudi Arabia Clinical and Chemical Pathology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt hoiydaahmedelmenshawy@gmail.com. 2. Neurology Department, Faculty of Medicine, Cairo University, Egypt. 3. Neurology Department, Faculty of Medicine, Fayoum University, Egypt. 4. Department of Biochemistry, Research Institute of Ophthalmology, Egypt. 5. Clinical Pathology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Abstract
BACKGROUND: Vascular endothelial growth factor A stimulates angiogenesis, but is also pro-inflammatory and plays an important role in the development of neurological disease. This study aimed to investigate whether vascular endothelial growth factor A mRNA expression could be used as a marker for the prediction of susceptibility to multiple sclerosis and relate vascular endothelial growth factor to the clinical phases of multiple sclerosis. METHODS: This was a cross-sectional study, consisting of a total of 60 subjects with multiple sclerosis and 20 healthy controls. Subjects were subjected to history taking, neurological examination and peripheral blood sampling for vascular endothelial growth factor A mRNA gene expression. Vascular endothelial growth factor A gene expression was measured by real-time polymerase chain reaction using the SYBR Green technique. RESULTS: Vascular endothelial growth factor A mRNA gene expression level was significantly lower in the multiple sclerosis group than in the healthy control group (P < 0.001). Vascular endothelial growth factor A mRNA gene expression level was higher in relapsing remitting multiple sclerosis (RRMS) patients than in those in remission (P < 0.001) and in relapsing remitting multiple sclerosis compared with secondary progressive multiple sclerosis (P < 0.001). There was no correlation between vascular endothelial growth factor A gene expression levels and duration of disease, multiple sclerosis progression index or expanded disability status scale. CONCLUSIONS: A lower vascular endothelial growth factor A mRNA gene expression level was independently associated with a higher risk of multiple sclerosis.
BACKGROUND:Vascular endothelial growth factor A stimulates angiogenesis, but is also pro-inflammatory and plays an important role in the development of neurological disease. This study aimed to investigate whether vascular endothelial growth factor A mRNA expression could be used as a marker for the prediction of susceptibility to multiple sclerosis and relate vascular endothelial growth factor to the clinical phases of multiple sclerosis. METHODS: This was a cross-sectional study, consisting of a total of 60 subjects with multiple sclerosis and 20 healthy controls. Subjects were subjected to history taking, neurological examination and peripheral blood sampling for vascular endothelial growth factor A mRNA gene expression. Vascular endothelial growth factor A gene expression was measured by real-time polymerase chain reaction using the SYBR Green technique. RESULTS:Vascular endothelial growth factor A mRNA gene expression level was significantly lower in the multiple sclerosis group than in the healthy control group (P < 0.001). Vascular endothelial growth factor A mRNA gene expression level was higher in relapsing remitting multiple sclerosis (RRMS) patients than in those in remission (P < 0.001) and in relapsing remitting multiple sclerosis compared with secondary progressive multiple sclerosis (P < 0.001). There was no correlation between vascular endothelial growth factor A gene expression levels and duration of disease, multiple sclerosis progression index or expanded disability status scale. CONCLUSIONS: A lower vascular endothelial growth factor A mRNA gene expression level was independently associated with a higher risk of multiple sclerosis.